

DEPARTMENT OF HEALTH AND HUMAN SERVICES FOOD AND DRUG ADMINISTRATION, FIELD OPERATIONS BRANCH, COMPLIANCE TEAM

HF1-35 SIIIA T1757 M COMPLIANCE TEAM B Elysian Fields Avenue

4298 Elysian Fields Avenue New Orleans, LA 70122 Telephone (504) 589-7166 Fax (504) 589-4657

May 1, 1998

WARNING LETTER NO. 98-NOL-19

CERTIFIED MAIL
RETURN RECEIPT REQUESTED

Mr. Tom Stanley, President Hall-Buck Marine Services P.O. Box 625 Sorrento, LA 70778

Dear Mr. Stanley:

A Food and Drug Administration (FDA) investigator performed an inspection of the vessel watering point at Hall-Buck Marine, Inc., Globalflex Bulk Handling Terminal, 1770 Highway 44, Reserve, Louisiana on April 23, 1998. The observations made during the inspection are in violation of the Public Health Service Act and the Food Drug and Cosmetic Act as promulgated in Title 21, Code of Federal Regulations, Parts 1240 and 1250.

During the inspection, the following violations were noted:

- 1) Potable and non-potable hydrants on the same dock are not identified for their intended use;
- 2) No cap and keeper chain on the potable water outlet.

The list of inspectional observations, identified above, is not intended to be an all-inclusive list of the conditions observed at your facility. It is your responsibility to assure adherence with all requirements of the regulations.

Based on the inspectional findings, we are classifying your facility as **PROVISIONAL** for interstate carrier use for a period of thirty (30) days. "Provisional" means that the facility may continue to operate; however, significant correction of violations must be made by the expiration date. On or about that date, a reinspection of this facility will be conducted to assure that corrections meet FDA requirements. If significant corrections are not made by the time of the next inspection, the facility will be reclassified as NON-APPROVED for carrier use.

Please advise this office within fifteen (15) days of the receipt of this letter regarding the measures you have implemented to correct the violations and to assure that such violations will not recur. Your response should include a discussion of delays you foresee in achieving correction, and a deadline by which correction can be expected. Your response should be directed to Nicole F. Hardin, Compliance Officer, U.S. Food and Drug Administration, 4298 Elysian Fields Avenue, New Orleans, Louisiana 70122-3896.

Sincerely,

James E. Gamet
District Director
New Orleans District

/ker

Enclosure: FDA-483